T4	total-participants 542 545	155
T5	eligibility 546 623	postmenopausal women affected by metabolic syndrome at risk of breast cancer,
T6	intervention-participants 794 796	77
T7	control 805 812	placebo
T8	control-participants 814 816	78
T9	outcome-Measure 886 967	reduction of more than 20% of the HOMA-IR index and of triglycerides serum levels
T12	outcome 1174 1191	HOMA-IR reduction
T13	outcome 1275 1294	serum insulin level
T1	intervention 15 45	inositol and alpha lipoic acid
T2	outcome 1340 1353	triglycerides
T3	outcome 1442 1457	HDL cholesterol
T14	outcome 1558 1577	waist circumference
T15	outcome 1582 1597	waist-hip ratio
T10	outcome-Measure 1011 1069	improvement of high-density lipoprotein cholesterol levels
T11	outcome-Measure 1078 1114	reduction of anthropometric features
